PET with Different Radiopharmaceuticals in Neuroendocrine Neoplasms: An Umbrella Review of Published Meta-Analyses

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Oct 23

PMID 34680321

Citations 20

Authors

Giorgio Treglia

Ramin Sadeghi

Francesco Giovinazzo

Federica Galiandro

Salvatore Annunziata

Barbara Muoio

Alexander Stephan Kroiss

Affiliations

Soon will be listed here.

Abstract

Background: Several meta-analyses have reported quantitative data about the diagnostic performance, the prognostic value, the impact on management and the safety of positron emission tomography (PET) including related hybrid modalities (PET/CT or PET/MRI) using different radiopharmaceuticals in patients with neuroendocrine neoplasms. We performed an umbrella review of published meta-analyses to provide an evidence-based summary.

Methods: A comprehensive literature search of meta-analyses listed in PubMed/MEDLINE and Cochrane Library databases was carried out (last search date: 30 June 2021).

Results: Thirty-four published meta-analyses were selected and summarized. About the diagnostic performance: Ga-SSA PET yields high diagnostic performance in patients with NETs and PGL; F-FDOPA PET yields good diagnostic performance in patients with intestinal NETs, PGL, NB, being the best available PET method in detecting rMTC; Ga-exendin-4 PET has good diagnostic accuracy in detecting insulinomas; F-FDG PET has good diagnostic performance in detecting aggressive neuroendocrine neoplasms. About the prognostic value: Ga-SSA PET has a recognized prognostic value in well-differentiated NETs, whereas F-FDG PET has a recognized prognostic value in aggressive neuroendocrine neoplasms. A significant clinical impact of Ga-SSA PET and related hybrid modalities in patients with NETs was demonstrated. There are no major toxicities or safety issues related to the use of PET radiopharmaceuticals in patients with neuroendocrine neoplasms.

Conclusions: Evidence-based data support the use of PET with different radiopharmaceuticals in patients with neuroendocrine neoplasms with specific indications for each radiopharmaceutical.

Citing Articles

Detection of cardiac neuroendocrine tumour metastases by somatostatin receptor PET/CT: a systematic review and meta-analysis.

Campanale D, Imperiale A, Albano D, Rizzo A, Piccardo A, Treglia G Front Med (Lausanne). 2024; 11:1491181.

PMID: 39473497 PMC: 11518709. DOI: 10.3389/fmed.2024.1491181.

Advancements in Neuroendocrine Neoplasms: Imaging and Future Frontiers.

Asmundo L, Rizzetto F, Blake M, Anderson M, Mojtahed A, Bradley W J Clin Med. 2024; 13(11).

PMID: 38892992 PMC: 11172657. DOI: 10.3390/jcm13113281.

Endocrinology application of molecular imaging: current role of PET/CT.

Calderoni L, Giovanella L, Fanti S J Endocrinol Invest. 2024; 47(10):2383-2396.

PMID: 38837101 PMC: 11393017. DOI: 10.1007/s40618-024-02400-8.

Diagnostic yield of FAP-guided positron emission tomography in thyroid cancer: a systematic review.

Rizzo A, Albano D, Dondi F, Cioffi M, Muoio B, Annunziata S Front Med (Lausanne). 2024; 11:1381863.

PMID: 38590320 PMC: 10999586. DOI: 10.3389/fmed.2024.1381863.

Real-Life Use of [68Ga]Ga-DOTANOC PET/CT in Confirmed and Suspected NETs from a Prospective 5-Year Electronic Archive at an ENETS Center of Excellence: More Than 2000 Scans in More Than 1500 Patients.

Bonazzi N, Fortunati E, Zanoni L, Argalia G, Calabro D, Tabacchi E Cancers (Basel). 2024; 16(4).

PMID: 38398092 PMC: 10886517. DOI: 10.3390/cancers16040701.

References

Taieb D, Jha A, Treglia G, Pacak K . Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. Endocr Relat Cancer. 2019; 26(11):R627-R652. PMC: 7002202. DOI: 10.1530/ERC-19-0165. View

Taieb D, Hicks R, Hindie E, Guillet B, Avram A, Ghedini P . European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2019; 46(10):2112-2137. PMC: 7446938. DOI: 10.1007/s00259-019-04398-1. View

Bauckneht M, Albano D, Annunziata S, Santo G, Guglielmo P, Frantellizzi V . Somatostatin Receptor PET/CT Imaging for the Detection and Staging of Pancreatic NET: A Systematic Review and Meta-Analysis. Diagnostics (Basel). 2020; 10(8). PMC: 7459584. DOI: 10.3390/diagnostics10080598. View

Rindi G, Inzani F . Neuroendocrine neoplasm update: toward universal nomenclature. Endocr Relat Cancer. 2020; 27(6):R211-R218. DOI: 10.1530/ERC-20-0036. View

Fusar-Poli P, Radua J . Ten simple rules for conducting umbrella reviews. Evid Based Ment Health. 2018; 21(3):95-100. PMC: 10270421. DOI: 10.1136/ebmental-2018-300014. View

Agrawal K, Padhy B, Meher B, Mohanty R . Diagnostic utility of Ga-68 DOTA-SSTR and F-18 FDG PET/CT in the detection of culprit tumours causing osteomalacia: a systematic review and meta-analysis. Nucl Med Commun. 2021; 42(6):646-655. DOI: 10.1097/MNM.0000000000001379. View

Blomberg B, Moghbel M, Saboury B, Stanley C, Alavi A . The value of radiologic interventions and (18)F-DOPA PET in diagnosing and localizing focal congenital hyperinsulinism: systematic review and meta-analysis. Mol Imaging Biol. 2012; 15(1):97-105. PMC: 3553406. DOI: 10.1007/s11307-012-0572-0. View

Han S, Suh C, Woo S, Kim Y, Lee J . Performance of Ga-DOTA-Conjugated Somatostatin Receptor-Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis. J Nucl Med. 2018; 60(3):369-376. DOI: 10.2967/jnumed.118.211706. View

Christensen T, Andersen P, Langer S, Fischer B . Prognostic Value of F-FDG-PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current Literature. Diagnostics (Basel). 2021; 11(2). PMC: 7912276. DOI: 10.3390/diagnostics11020174. View

10.

Lu Y, Chen J, Liang J, Chu S, Lin W, Kao C . 18F-FDG PET or PET/CT for detecting extensive disease in small-cell lung cancer: a systematic review and meta-analysis. Nucl Med Commun. 2014; 35(7):697-703. DOI: 10.1097/MNM.0000000000000122. View

11.

Jiang Y, Hou G, Cheng W . The utility of 18F-FDG and 68Ga-DOTA-Peptide PET/CT in the evaluation of primary pulmonary carcinoid: A systematic review and meta-analysis. Medicine (Baltimore). 2019; 98(10):e14769. PMC: 6417554. DOI: 10.1097/MD.0000000000014769. View

12.

Treglia G, Villani M, Giordano A, Rufini V . Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis. Endocrine. 2012; 42(3):535-45. DOI: 10.1007/s12020-012-9671-6. View

13.

Treglia G, Cocciolillo F, Di Nardo F, Poscia A, de Waure C, Giordano A . Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis. Acad Radiol. 2012; 19(10):1290-9. DOI: 10.1016/j.acra.2012.05.008. View

14.

Jiang Y, Hou G, Cheng W . Performance of 68Ga-DOTA-SST PET/CT, octreoscan SPECT/CT and 18F-FDG PET/CT in the detection of culprit tumors causing osteomalacia: a meta-analysis. Nucl Med Commun. 2020; 41(4):370-376. PMC: 7077972. DOI: 10.1097/MNM.0000000000001163. View

15.

Santhanam P, Taieb D, Giovanella L, Treglia G . PET imaging in ectopic Cushing syndrome: a systematic review. Endocrine. 2015; 50(2):297-305. DOI: 10.1007/s12020-015-0689-4. View

16.

Bar-Sever Z, Biassoni L, Shulkin B, Kong G, Hofman M, Lopci E . Guidelines on nuclear medicine imaging in neuroblastoma. Eur J Nucl Med Mol Imaging. 2018; 45(11):2009-2024. DOI: 10.1007/s00259-018-4070-8. View

17.

Ma H, Kan Y, Yang J . Clinical value of Ga-DOTA-SSTR PET/CT in the diagnosis and detection of neuroendocrine tumors of unknown primary origin: a systematic review and meta-analysis. Acta Radiol. 2020; 62(9):1217-1228. DOI: 10.1177/0284185120958412. View

18.

Yang J, Kan Y, Ge B, Yuan L, Li C, Zhao W . Diagnostic role of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in patients with neuroendocrine tumors: a meta-analysis. Acta Radiol. 2013; 55(4):389-98. DOI: 10.1177/0284185113496679. View

19.

Treglia G, Goichot B, Giovanella L, Hindie E, Jha A, Pacak K . Prognostic and predictive value of nuclear imaging in endocrine oncology. Endocrine. 2019; 67(1):9-19. PMC: 7441826. DOI: 10.1007/s12020-019-02131-4. View

20.

Meyer M, Nicod Lalonde M, Testart N, Jreige M, Kamani C, Boughdad S . Detection Rate of Culprit Tumors Causing Osteomalacia Using Somatostatin Receptor PET/CT: Systematic Review and Meta-Analysis. Diagnostics (Basel). 2019; 10(1). PMC: 7169446. DOI: 10.3390/diagnostics10010002. View